首页 > 最新文献

JAC-Antimicrobial Resistance最新文献

英文 中文
Exploring factors affecting the national implementation and uptake of an antimicrobial stewardship training programme to primary care providers in England. 探索影响国家实施和吸收抗菌药物管理培训计划的因素在英格兰初级保健提供者。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-12 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf212
Jade Meadows, Ming Xuan Lee, Raheelah Ahmad, Helena Wehling, Nina Zhu, Jo Taylor-Egbeyemi, Louise E Smith, Dale Weston, Kieran Hand, Donna M Lecky

Background: Most antibiotics are prescribed in the primary care setting. In response to the global threat of antimicrobial resistance (AMR), the TARGET (Treat Antibiotics Responsibly, Guidance, Education and Tools) antimicrobial stewardship (AMS) training toolkit for primary care clinicians was rolled out in England in 2022. This study aimed to understand preconceived, as well as actual, factors influencing the roll out of training to improve and inform implementation strategies of this and future initiatives.

Methods: Two workshops were held: one at the launch (22 participants) in 2022 and another 18 months (14 participants) into intervention roll out, in 2024. Qualitative data were collected using the Theoretical Domains Framework to identify barriers and facilitators, and the Expert Recommendations for Implementing Change Framework to identify strategies for supporting change.

Results: Anticipated barriers, at launch, included lack of secure knowledge and, at a national level, confidence in presenting training content. Anticipated enablers were appointing regional champions and linking training to continuing professional development. Eighteen months later, barriers related to the effort needed to both implement the training and maintaining knowledge of evolving AMR evidence. Promoting the benefits of the training and financial incentives were cited as facilitators. Across both workshops, barriers were a lack of capacity and time.Purposive strategies most employed concentrated on educating stakeholders, providing support and development of stakeholder relationships. Strategies least employed were financial strategies and changing the regional level infrastructure.

Conclusions: Overall, the implementation of a national training programme requires support, both centrally and regionally, to be successful. Regional variation in priorities and practical issues should be acknowledged when implementing interventions nationwide.

背景:大多数抗生素是在初级保健机构开的。为应对抗菌素耐药性(AMR)的全球威胁,英国于2022年推出了针对初级保健临床医生的TARGET(负责任地对待抗生素、指南、教育和工具)抗菌素管理(AMS)培训工具包。这项研究的目的是了解影响开展培训的先入为主和实际存在的因素,以改进这一举措和未来举措的实施战略,并为其提供信息。方法:举办两次研讨会:一次是在2022年启动时(22名参与者),另一次是在干预措施推出后18个月(14名参与者),即2024年。使用理论领域框架收集定性数据,以确定障碍和促进因素,并使用实施变革框架的专家建议来确定支持变革的策略。结果:预期的障碍,在启动时,包括缺乏安全的知识,并在国家一级,在提出培训内容的信心。预期的推动因素是任命区域冠军,并将培训与持续的专业发展联系起来。18个月后,与实施培训和维护不断发展的抗菌素耐药性证据知识所需的努力有关的障碍出现了。促进培训和财政奖励的好处被认为是促进因素。在这两个研讨会上,障碍是缺乏能力和时间。大多数采用的有目的策略集中于教育利益相关者,提供支持和发展利益相关者关系。采用最少的战略是财政战略和改变区域一级的基础设施。结论:总的来说,国家培训方案的执行需要得到中央和区域两方面的支持才能成功。在全国范围内实施干预措施时,应承认优先事项和实际问题的区域差异。
{"title":"Exploring factors affecting the national implementation and uptake of an antimicrobial stewardship training programme to primary care providers in England.","authors":"Jade Meadows, Ming Xuan Lee, Raheelah Ahmad, Helena Wehling, Nina Zhu, Jo Taylor-Egbeyemi, Louise E Smith, Dale Weston, Kieran Hand, Donna M Lecky","doi":"10.1093/jacamr/dlaf212","DOIUrl":"10.1093/jacamr/dlaf212","url":null,"abstract":"<p><strong>Background: </strong>Most antibiotics are prescribed in the primary care setting. In response to the global threat of antimicrobial resistance (AMR), the TARGET (Treat Antibiotics Responsibly, Guidance, Education and Tools) antimicrobial stewardship (AMS) training toolkit for primary care clinicians was rolled out in England in 2022. This study aimed to understand preconceived, as well as actual, factors influencing the roll out of training to improve and inform implementation strategies of this and future initiatives.</p><p><strong>Methods: </strong>Two workshops were held: one at the launch (22 participants) in 2022 and another 18 months (14 participants) into intervention roll out, in 2024. Qualitative data were collected using the Theoretical Domains Framework to identify barriers and facilitators, and the Expert Recommendations for Implementing Change Framework to identify strategies for supporting change.</p><p><strong>Results: </strong>Anticipated barriers, at launch, included lack of secure knowledge and, at a national level, confidence in presenting training content. Anticipated enablers were appointing regional champions and linking training to continuing professional development. Eighteen months later, barriers related to the effort needed to both implement the training and maintaining knowledge of evolving AMR evidence. Promoting the benefits of the training and financial incentives were cited as facilitators. Across both workshops, barriers were a lack of capacity and time.Purposive strategies most employed concentrated on educating stakeholders, providing support and development of stakeholder relationships. Strategies least employed were financial strategies and changing the regional level infrastructure.</p><p><strong>Conclusions: </strong>Overall, the implementation of a national training programme requires support, both centrally and regionally, to be successful. Regional variation in priorities and practical issues should be acknowledged when implementing interventions nationwide.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf212"},"PeriodicalIF":3.3,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12699993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Social media as a means of sharing information on antimicrobial resistance and appropriate antibiotic use: a systematic review. 社交媒体作为分享抗微生物药物耐药性和适当使用抗生素信息的手段:一项系统综述
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-12 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf237
Ellie L Tang, Christopher Agbakwa, Chinwendu Courage Ngozi, Diane Ashiru-Oredope, Misheck J Nkhata, Lawrence Achilles Nnyanzi

Background: Use of social media to access health information is increasing. This systematic review aims to assess the availability of social media-based information related to antimicrobial resistance (AMR) and antibiotic use aimed at members of the public. It also looked to determine whether sharing information related to AMR and antibiotic use on social media improves public knowledge.

Methods: MEDLINE, Embase and PsycINFO were searched on 24 May 2024. Google Scholar was searched on 4 October 2024. All primary studies published between January 2013 and May 2024 that outlined AMR or antibiotic-related information on social media or assessed the effectiveness of social media at improving knowledge and attitudes towards AMR and antibiotic use were eligible for inclusion. Risk of bias assessment was conducted using the mixed-methods appraisal tool. A narrative synthesis was used to describe the studies.

Results: In total, 624 papers were identified with 607 records removed during de-duplication and screening. Identified papers assessed the reach of and engagement with social media posts (n = 7), attitudes towards antibiotic use (n = 4), learning materials (n = 3) and the effectiveness of social media at increasing public knowledge (n = 2). Common misconceptions were identified, including how AMR develops and the conditions that antibiotics can be used to treat.

Conclusions: This review highlights that a range of information relating to AMR and antibiotic use is available on social media, including false information. However, the impact of exposure to social media content on knowledge, attitudes and behaviours towards AMR and appropriate antibiotic use remains unclear.

背景:越来越多的人使用社交媒体获取卫生信息。本系统综述旨在评估针对公众的与抗菌素耐药性(AMR)和抗生素使用有关的基于社交媒体的信息的可获得性。它还试图确定在社交媒体上分享与抗菌素耐药性和抗生素使用有关的信息是否能提高公众的认识。方法:2024年5月24日检索MEDLINE、Embase和PsycINFO。谷歌Scholar于2024年10月4日检索。2013年1月至2024年5月期间发表的所有在社交媒体上概述AMR或抗生素相关信息或评估社交媒体在提高对AMR和抗生素使用的认识和态度方面的有效性的初步研究都有资格纳入。偏倚风险评估采用混合方法评估工具。采用叙事综合的方法来描述这些研究。结果:共鉴定论文624篇,删除记录607条。确定的论文评估了社交媒体帖子的覆盖范围和参与度(n = 7),对抗生素使用的态度(n = 4),学习材料(n = 3)以及社交媒体在增加公众知识方面的有效性(n = 2)。确定了常见的误解,包括抗菌素耐药性如何发展以及抗生素可用于治疗的病症。结论:本综述强调,在社交媒体上可以获得与AMR和抗生素使用有关的一系列信息,包括虚假信息。然而,接触社交媒体内容对抗菌素耐药性和适当使用抗生素的知识、态度和行为的影响尚不清楚。
{"title":"Social media as a means of sharing information on antimicrobial resistance and appropriate antibiotic use: a systematic review.","authors":"Ellie L Tang, Christopher Agbakwa, Chinwendu Courage Ngozi, Diane Ashiru-Oredope, Misheck J Nkhata, Lawrence Achilles Nnyanzi","doi":"10.1093/jacamr/dlaf237","DOIUrl":"10.1093/jacamr/dlaf237","url":null,"abstract":"<p><strong>Background: </strong>Use of social media to access health information is increasing. This systematic review aims to assess the availability of social media-based information related to antimicrobial resistance (AMR) and antibiotic use aimed at members of the public. It also looked to determine whether sharing information related to AMR and antibiotic use on social media improves public knowledge.</p><p><strong>Methods: </strong>MEDLINE, Embase and PsycINFO were searched on 24 May 2024. Google Scholar was searched on 4 October 2024. All primary studies published between January 2013 and May 2024 that outlined AMR or antibiotic-related information on social media or assessed the effectiveness of social media at improving knowledge and attitudes towards AMR and antibiotic use were eligible for inclusion. Risk of bias assessment was conducted using the mixed-methods appraisal tool. A narrative synthesis was used to describe the studies.</p><p><strong>Results: </strong>In total, 624 papers were identified with 607 records removed during de-duplication and screening. Identified papers assessed the reach of and engagement with social media posts (<i>n</i> = 7), attitudes towards antibiotic use (<i>n</i> = 4), learning materials (<i>n</i> = 3) and the effectiveness of social media at increasing public knowledge (<i>n</i> = 2). Common misconceptions were identified, including how AMR develops and the conditions that antibiotics can be used to treat.</p><p><strong>Conclusions: </strong>This review highlights that a range of information relating to AMR and antibiotic use is available on social media, including false information. However, the impact of exposure to social media content on knowledge, attitudes and behaviours towards AMR and appropriate antibiotic use remains unclear.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf237"},"PeriodicalIF":3.3,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12700105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful outpatient parenteral antimicrobial therapy with rezafungin for chronic pulmonary aspergillosis: a case report and health economic assessment. 慢性肺曲霉病的成功门诊静脉外抗菌治疗瑞扎芬:一个病例报告和健康经济评估。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-09 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf234
Sheonagh MacPhail Law, Annabel Choyce, Hana Barzinji, Huw Ellis, Chris Kosmidis, Ronald Andrew Seaton

Background: Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by Aspergillus fungal infection with high morbidity and mortality. Treatment options include antifungal azoles, polyenes and echinocandins. Rezafungin is a novel, once-weekly echinocandin that may benefit CPA management in outpatient parenteral antimicrobial therapy (OPAT) services.

Objectives: To report a case where rezafungin was potentially effective in managing CPA for a patient with limited treatment options, and to estimate the health economic impact of rezafungin versus once-daily echinocandin in an OPAT setting.

Patients and methods: We discuss a patient with CPA, diagnosed in 2020, with frequent episodes of haemoptysis, dyspnoea, productive cough and lethargy with progressive bilateral pulmonary cavitatory lesions and nodules treated with rezafungin over 12 weeks via OPAT. Costs to deliver once-weekly rezafungin compared with once-daily caspofungin in the OPAT clinic were compared.

Results: Symptoms improved significantly after 12 weeks of rezafungin, with no further emergency visits, versus eight in the year prior due to CPA symptoms. Aspergillus serology (IgG) improved and computerized tomography imaging showed slight improvement in the degree of consolidation surrounding the cavities. Daily OPAT costs increased by £13.71 for rezafungin compared with caspofungin. This was offset by greater patient convenience and improved OPAT clinic capacity.

Conclusions: Rezafungin may be a novel, well-tolerated and cost-effective echinocandin treatment for CPA in patients needing OPAT and with limited treatment options. Further clinical studies are required for robust evaluation of this novel echinocandin in CPA.

背景:慢性肺曲霉病(Chronic pulmonary aspergillosis, CPA)是一种由曲霉真菌感染引起的严重肺部疾病,发病率和死亡率高。治疗方案包括抗真菌唑类药物、多烯类药物和棘白菌素。Rezafungin是一种新的,每周一次的棘白菌素,可能有利于门诊肠外抗菌治疗(OPAT)服务的CPA管理。目的:报告一个病例,rezafungin在治疗方案有限的CPA患者中可能有效,并评估在OPAT环境中,rezafungin与每日一次的刺青素的健康经济影响。患者和方法:我们讨论了一名CPA患者,于2020年诊断,频繁咯血,呼吸困难,咳嗽和嗜睡,并通过OPAT治疗了12周的进行性双侧肺空化病变和结节。比较了OPAT诊所每周一次的rezafungin和每天一次的caspofungin的成本。结果:rezafungin 12周后症状明显改善,没有进一步的急诊就诊,而一年前由于CPA症状8周。曲霉血清(IgG)改善,计算机断层成像显示空腔周围的实变程度略有改善。与caspofungin相比,rezafungin的每日OPAT费用增加了13.71英镑。这被更大的病人便利性和改进的OPAT诊所能力所抵消。结论:Rezafungin可能是一种新的、耐受性良好且具有成本效益的针刺白菌素治疗需要OPAT且治疗方案有限的CPA患者。这种新型棘白菌素在CPA中的应用需要进一步的临床研究。
{"title":"Successful outpatient parenteral antimicrobial therapy with rezafungin for chronic pulmonary aspergillosis: a case report and health economic assessment.","authors":"Sheonagh MacPhail Law, Annabel Choyce, Hana Barzinji, Huw Ellis, Chris Kosmidis, Ronald Andrew Seaton","doi":"10.1093/jacamr/dlaf234","DOIUrl":"10.1093/jacamr/dlaf234","url":null,"abstract":"<p><strong>Background: </strong>Chronic pulmonary aspergillosis (CPA) is a serious lung disorder caused by <i>Aspergillus</i> fungal infection with high morbidity and mortality. Treatment options include antifungal azoles, polyenes and echinocandins. Rezafungin is a novel, once-weekly echinocandin that may benefit CPA management in outpatient parenteral antimicrobial therapy (OPAT) services.</p><p><strong>Objectives: </strong>To report a case where rezafungin was potentially effective in managing CPA for a patient with limited treatment options, and to estimate the health economic impact of rezafungin versus once-daily echinocandin in an OPAT setting.</p><p><strong>Patients and methods: </strong>We discuss a patient with CPA, diagnosed in 2020, with frequent episodes of haemoptysis, dyspnoea, productive cough and lethargy with progressive bilateral pulmonary cavitatory lesions and nodules treated with rezafungin over 12 weeks via OPAT. Costs to deliver once-weekly rezafungin compared with once-daily caspofungin in the OPAT clinic were compared.</p><p><strong>Results: </strong>Symptoms improved significantly after 12 weeks of rezafungin, with no further emergency visits, versus eight in the year prior due to CPA symptoms. Aspergillus serology (IgG) improved and computerized tomography imaging showed slight improvement in the degree of consolidation surrounding the cavities. Daily OPAT costs increased by £13.71 for rezafungin compared with caspofungin. This was offset by greater patient convenience and improved OPAT clinic capacity.</p><p><strong>Conclusions: </strong>Rezafungin may be a novel, well-tolerated and cost-effective echinocandin treatment for CPA in patients needing OPAT and with limited treatment options. Further clinical studies are required for robust evaluation of this novel echinocandin in CPA.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf234"},"PeriodicalIF":3.3,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12687343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145723380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016-23. 2016-23年荷兰MRSA分离株对夫西地酸的耐药性呈上升趋势。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-05 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf229
F Velthuis, I M Nauta, W Altorf-van der Kuil, D W Notermans, R D Zwittink, A F Schoffelen, S C de Greeff

Objectives: Recently, several MRSA community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance percentages among MRSA isolates in the Netherlands.

Materials and methods: Data on routine bacteriological cultures between 2016 and 2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS-AR). Fusidic acid resistance percentages per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP). Trends were determined using logistic regression and compared with trends among MSSA isolates.

Results: We found an increase in fusidic acid resistance among MRSA isolates from 15% (2016) to 29% (2023) (P < 0.001), which differed significantly (P < 0.001) from the trend among MSSA isolates (10%-12%). An increase was also found in MRSA WPS-GP isolates, both among young children and the population of 13-64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07-1.14, P < 0.001) and among MRSA WPS-GP isolates (OR = 1.14, 1.07-1.21, P < 0.001).

Conclusions: In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.

目的:最近,荷兰发生了几次MRSA社区暴发,其中一次是由一种对夫西地酸耐药的脓疱引起的MRSA菌株引起的。由于夫西地酸和氟氯西林是脓疱疮的主要治疗选择,增加耐药性限制了治疗的可能性。我们检查了荷兰MRSA分离株中夫西地酸耐药百分比的趋势。材料和方法:从国家抗微生物药物耐药性监测系统(ISIS-AR)中提取2016 - 2023年30个实验室的常规细菌培养数据。每年计算所有MRSA分离株的总体和每个年龄组的耐夫西地酸百分比,更具体地说,计算全科医生(WPS-GP)收集的伤口/脓液/皮肤样本中MRSA分离株的子集。使用逻辑回归确定趋势,并比较MSSA分离株的趋势。结果:MRSA分离株对夫西地酸的耐药率从2016年的15%上升至2023年的29% (P P P P)。结论:MRSA分离株对夫西地酸的耐药率呈上升趋势。由于脓疱疮的不良治疗可能会缓解(耐夫西地酸)MRSA的传播,因此需要格外警惕。
{"title":"Increasing trend in fusidic acid resistance among MRSA isolates in the Netherlands, 2016-23.","authors":"F Velthuis, I M Nauta, W Altorf-van der Kuil, D W Notermans, R D Zwittink, A F Schoffelen, S C de Greeff","doi":"10.1093/jacamr/dlaf229","DOIUrl":"10.1093/jacamr/dlaf229","url":null,"abstract":"<p><strong>Objectives: </strong>Recently, several MRSA community outbreaks occurred in the Netherlands, including one caused by an impetigo-causing MRSA strain resistant to fusidic acid. Since fusidic acid and flucloxacillin are the main treatment options for impetigo, increasing resistance limits treatment possibilities. We examined trends in fusidic acid resistance percentages among MRSA isolates in the Netherlands.</p><p><strong>Materials and methods: </strong>Data on routine bacteriological cultures between 2016 and 2023 from 30 laboratories were extracted from the national surveillance system on antimicrobial resistance (ISIS-AR). Fusidic acid resistance percentages per year were calculated both overall and per age group for all MRSA isolates, and more specific, for the subset of MRSA isolates from wound/pus/skin samples collected by general practitioners (WPS-GP). Trends were determined using logistic regression and compared with trends among MSSA isolates.</p><p><strong>Results: </strong>We found an increase in fusidic acid resistance among MRSA isolates from 15% (2016) to 29% (2023) (<i>P</i> < 0.001), which differed significantly (<i>P</i> < 0.001) from the trend among MSSA isolates (10%-12%). An increase was also found in MRSA WPS-GP isolates, both among young children and the population of 13-64 years old, but not among elderly. The trends remained significant after exclusion of isolates associated with known fusidic acid-resistant MRSA outbreaks, both among MRSA isolates overall (OR = 1.10, 95% CI: 1.07-1.14, <i>P</i> < 0.001) and among MRSA WPS-GP isolates (OR = 1.14, 1.07-1.21, <i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>In conclusion, an increasing trend in fusidic acid resistance was found among MRSA isolates. Since impaired treatment for impetigo might ease the spread of (fusidic acid-resistant) MRSA, extra vigilance is warranted.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf229"},"PeriodicalIF":3.3,"publicationDate":"2025-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12678940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The environmental impact of intravenous antimicrobial therapies: a comparison of OPAT and in-patient administration care pathways-right-to-reply. 静脉抗菌药物治疗的环境影响:OPAT和住院管理护理途径的比较-回复权。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-04 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf193
A Cole, J Aspin, S Laird, F Acri, S Galley, M Collins
{"title":"The environmental impact of intravenous antimicrobial therapies: a comparison of OPAT and in-patient administration care pathways-right-to-reply.","authors":"A Cole, J Aspin, S Laird, F Acri, S Galley, M Collins","doi":"10.1093/jacamr/dlaf193","DOIUrl":"https://doi.org/10.1093/jacamr/dlaf193","url":null,"abstract":"","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf193"},"PeriodicalIF":3.3,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12676003/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AMRrounds: What goes around comes back around-recurrent KPC-producing Salmonella bacteraemia. 周围:一种病一种病——复发性产生kpc的沙门氏菌血症。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-04 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf208
Ashley H Marx, Courtney N Dial, Brent Footer
{"title":"AMRrounds: What goes around comes back around-recurrent KPC-producing <i>Salmonella</i> bacteraemia.","authors":"Ashley H Marx, Courtney N Dial, Brent Footer","doi":"10.1093/jacamr/dlaf208","DOIUrl":"10.1093/jacamr/dlaf208","url":null,"abstract":"","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf208"},"PeriodicalIF":3.3,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12676005/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of different brands of clarithromycin tablets marketed in Ethiopia; implications for the future. 在埃塞俄比亚销售的不同品牌克拉霉素片的质量;对未来的影响。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-04 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf224
Workye Tsehayu Bayu, Gebremariam Ketema, Haile Kassahun, Johanna C Meyer, Brian Godman, Biset Asrade Mekonnen

Background: There are concerns with the availability of substandard antibiotics across Africa, including Ethiopia, exacerbating high levels of antimicrobial resistance (AMR). There are ongoing initiatives across Africa to reduce their availability to reduce AMR, including Pan-African registration, coordination with Interpol, and increasing surveillance. Consequently, the objective of the study was to evaluate the quality of different brands of clarithromycin tablets currently marketed in Ethiopia as a key antibiotic.

Methods: A total of 120 tablets of 12 different brands of clarithromycin 500 mg tablets were purchased from 12 different community pharmacies. Quality control tests, including visual inspection, thickness, diameter, hardness, friability, weight variation, disintegration, dissolution, and assays, were conducted at the Ethiopian Pharmaceutical Company's drug quality control laboratory on the sourced tablets. Tests were performed in accordance with the United States Pharmacopoeia (USP) and the World Health Organization's procedures.

Results: The identification test results confirmed the presence of the active pharmaceutical ingredients. The weight variation tests showed compliance with the USP limits. All clarithromycin brands and tablets met the USP requirements for hardness and disintegration times. The percentage content of all brands and tablets ranged from 95.14% to 100.44%, meeting the USP specifications. The dissolution tests also met required USP limits alongside factor (f1) factor (f2) values, which were within acceptable ranges.

Conclusion: As a result, all tested clarithromycin brands conformed with the required quality standards and were of acceptable quality. Consequently, these different brands of clarithromycin can be used to effectively treat patients and support ongoing national efforts to ensure antibiotic quality and strengthen AMR containment strategies.

背景:人们对包括埃塞俄比亚在内的整个非洲不合格抗生素的可获得性感到担忧,这加剧了高水平的抗菌素耐药性(AMR)。非洲各地正在采取行动减少抗生素耐药性,包括泛非登记、与国际刑警组织协调以及加强监测。因此,该研究的目的是评估目前在埃塞俄比亚作为关键抗生素销售的不同品牌克拉霉素片的质量。方法:从12个不同的社区药房采购12个不同品牌的克拉霉素500 mg片120片。质量控制试验,包括目视检查、厚度、直径、硬度、脆性、重量变化、崩解、溶出和测定,在埃塞俄比亚制药公司的药品质量控制实验室对来源的片剂进行了检验。试验是按照美国药典和世界卫生组织的程序进行的。结果:鉴定结果证实其有效成分的存在。重量变化试验符合美国药典标准。所有克拉霉素品牌和片剂的硬度和崩解时间均符合USP要求。各品牌和片剂的含量范围为95.14% ~ 100.44%,符合USP标准。除因子(f1)因子(f2)值外,溶出度试验也符合USP要求的限值,在可接受范围内。结论:经检验的克拉霉素品牌均符合质量标准,质量合格。因此,这些不同品牌的克拉霉素可用于有效治疗患者,并支持正在进行的国家努力,以确保抗生素质量和加强抗生素耐药性遏制战略。
{"title":"Quality of different brands of clarithromycin tablets marketed in Ethiopia; implications for the future.","authors":"Workye Tsehayu Bayu, Gebremariam Ketema, Haile Kassahun, Johanna C Meyer, Brian Godman, Biset Asrade Mekonnen","doi":"10.1093/jacamr/dlaf224","DOIUrl":"10.1093/jacamr/dlaf224","url":null,"abstract":"<p><strong>Background: </strong>There are concerns with the availability of substandard antibiotics across Africa, including Ethiopia, exacerbating high levels of antimicrobial resistance (AMR). There are ongoing initiatives across Africa to reduce their availability to reduce AMR, including Pan-African registration, coordination with Interpol, and increasing surveillance. Consequently, the objective of the study was to evaluate the quality of different brands of clarithromycin tablets currently marketed in Ethiopia as a key antibiotic.</p><p><strong>Methods: </strong>A total of 120 tablets of 12 different brands of clarithromycin 500 mg tablets were purchased from 12 different community pharmacies. Quality control tests, including visual inspection, thickness, diameter, hardness, friability, weight variation, disintegration, dissolution, and assays, were conducted at the Ethiopian Pharmaceutical Company's drug quality control laboratory on the sourced tablets. Tests were performed in accordance with the United States Pharmacopoeia (USP) and the World Health Organization's procedures.</p><p><strong>Results: </strong>The identification test results confirmed the presence of the active pharmaceutical ingredients. The weight variation tests showed compliance with the USP limits. All clarithromycin brands and tablets met the USP requirements for hardness and disintegration times. The percentage content of all brands and tablets ranged from 95.14% to 100.44%, meeting the USP specifications. The dissolution tests also met required USP limits alongside factor (f1) factor (f2) values, which were within acceptable ranges.</p><p><strong>Conclusion: </strong>As a result, all tested clarithromycin brands conformed with the required quality standards and were of acceptable quality. Consequently, these different brands of clarithromycin can be used to effectively treat patients and support ongoing national efforts to ensure antibiotic quality and strengthen AMR containment strategies.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf224"},"PeriodicalIF":3.3,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12676004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rapid systematic scoping review of the levels of bacterial antimicrobial resistance and antibiotic use among people in contact with the criminal justice system. 对与刑事司法系统接触的人群中细菌抗微生物药物耐药性和抗生素使用水平进行快速系统的范围审查。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-04 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf222
Clare Oliver-Williams, Maria Nasim, Michael Cook, Chantal Edge, Diane Ashiru-Oredope

Background: Antimicrobial resistance (AMR) poses a significant public health threat. Individuals in contact with the criminal justice system, including individuals in custody, prisons, jails or youth offending institutions, may be particularly vulnerable due to living conditions, behaviours and pre-existing health issues. This review assesses bacterial AMR and antibiotic use in this population.

Methods: A rapid systematic scoping review was conducted (OSF: https://doi.org/10.17605/OSF.IO/XHCFJ). Embase, Medline and Scopus were searched for studies published between 1 January 2010 and 28 September 2023. One author screened all records, with 10% dual screened. Included studies examined AMR bacteria or antibiotic use among people in contact with the criminal justice system (including people in custody, prisons, jails or youth offending institutes). Study quality was assessed using the Newcastle-Ottawa Scale and STROBE AMS checklist. Findings were synthesized narratively as evidence was limited and heterogeneous, which prohibited planned meta-analyses.

Results: Sixteen papers met inclusion criteria; eight were at lower risk of bias. Three studies examined antibiotic use, reporting common inappropriate prescribing (n = 1) and associations between recent antibiotic use and resistant infections (n = 2). Fourteen papers reported AMR findings, most with a focus on Mycobacterium tuberculosis and Staphylococcus aureus. Drug-resistant TB prevalence in prison populations ranged from 5.2% to 37% (n = 4). Methicillin resistant Staphylococcus aureus colonization ranged from 8.1% to 8.8% (n = 4). Other bacteria examined included Salmonella spp., Acinetobacter spp., Group A Streptococcus, and Mycoplasma genitalium.

Conclusions: People in contact with the criminal justice system face heightened risks of resistant bacterial infections. However, with only three studies addressing antibiotic use, evidence is limited. Addressing AMR in this group requires collaborative and targeted public health interventions.

背景:抗菌素耐药性(AMR)构成了重大的公共卫生威胁。与刑事司法系统接触的个人,包括在拘留所、监狱、拘留所或青少年犯罪机构中的个人,由于生活条件、行为和先前存在的健康问题,可能特别容易受到伤害。本综述评估了该人群的细菌AMR和抗生素使用情况。方法:进行快速系统的范围审查(OSF: https://doi.org/10.17605/OSF.IO/XHCFJ)。检索了2010年1月1日至2023年9月28日期间发表的Embase、Medline和Scopus。一位作者筛选了所有记录,10%进行了双重筛选。包括的研究调查了与刑事司法系统接触的人(包括在拘留所、监狱、拘留所或青少年犯罪研究所的人)的抗菌素耐药性细菌或抗生素使用情况。使用纽卡斯尔-渥太华量表和STROBE AMS检查表评估研究质量。由于证据有限且异质性,研究结果以叙述的方式综合,这禁止了计划的荟萃分析。结果:16篇论文符合纳入标准;其中8例偏倚风险较低。三项研究调查了抗生素的使用,报告了常见的不当处方(n = 1)和近期抗生素使用与耐药感染之间的关系(n = 2)。14篇论文报道了AMR的发现,大多数集中在结核分枝杆菌和金黄色葡萄球菌。监狱人群中耐药结核病患病率从5.2%到37%不等(n = 4)。耐甲氧西林金黄色葡萄球菌的定植范围为8.1%至8.8% (n = 4)。其他检测的细菌包括沙门氏菌、不动杆菌、A群链球菌和生殖支原体。结论:与刑事司法系统接触的人面临更高的耐药细菌感染风险。然而,只有三项研究涉及抗生素的使用,证据有限。解决这一群体的抗菌素耐药性问题需要协作性和针对性的公共卫生干预措施。
{"title":"A rapid systematic scoping review of the levels of bacterial antimicrobial resistance and antibiotic use among people in contact with the criminal justice system.","authors":"Clare Oliver-Williams, Maria Nasim, Michael Cook, Chantal Edge, Diane Ashiru-Oredope","doi":"10.1093/jacamr/dlaf222","DOIUrl":"10.1093/jacamr/dlaf222","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial resistance (AMR) poses a significant public health threat. Individuals in contact with the criminal justice system, including individuals in custody, prisons, jails or youth offending institutions, may be particularly vulnerable due to living conditions, behaviours and pre-existing health issues. This review assesses bacterial AMR and antibiotic use in this population.</p><p><strong>Methods: </strong>A rapid systematic scoping review was conducted (OSF: https://doi.org/10.17605/OSF.IO/XHCFJ). Embase, Medline and Scopus were searched for studies published between 1 January 2010 and 28 September 2023. One author screened all records, with 10% dual screened. Included studies examined AMR bacteria or antibiotic use among people in contact with the criminal justice system (including people in custody, prisons, jails or youth offending institutes). Study quality was assessed using the Newcastle-Ottawa Scale and STROBE AMS checklist. Findings were synthesized narratively as evidence was limited and heterogeneous, which prohibited planned meta-analyses.</p><p><strong>Results: </strong>Sixteen papers met inclusion criteria; eight were at lower risk of bias. Three studies examined antibiotic use, reporting common inappropriate prescribing (<i>n</i> = 1) and associations between recent antibiotic use and resistant infections (<i>n</i> = 2). Fourteen papers reported AMR findings, most with a focus on <i>Mycobacterium tuberculosis</i> and <i>Staphylococcus aureus</i>. Drug-resistant TB prevalence in prison populations ranged from 5.2% to 37% (<i>n</i> = 4). Methicillin resistant <i>Staphylococcus aureus</i> colonization ranged from 8.1% to 8.8% (<i>n</i> = 4). Other bacteria examined included <i>Salmonella</i> spp., <i>Acinetobacter</i> spp., <i>Group A Streptococcus</i>, and <i>Mycoplasma genitalium</i>.</p><p><strong>Conclusions: </strong>People in contact with the criminal justice system face heightened risks of resistant bacterial infections. However, with only three studies addressing antibiotic use, evidence is limited. Addressing AMR in this group requires collaborative and targeted public health interventions.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf222"},"PeriodicalIF":3.3,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12676007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Understanding antimicrobial resistance education among medical and veterinary students in Norway: a cross-sectional survey. 更正:了解挪威医学和兽医学生的抗微生物药物耐药性教育:一项横断面调查。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-04 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf232

[This corrects the article DOI: 10.1093/jacamr/dlaf211.].

[更正文章DOI: 10.1093/jacamr/dlaf211.]。
{"title":"Correction to: Understanding antimicrobial resistance education among medical and veterinary students in Norway: a cross-sectional survey.","authors":"","doi":"10.1093/jacamr/dlaf232","DOIUrl":"https://doi.org/10.1093/jacamr/dlaf232","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/jacamr/dlaf211.].</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf232"},"PeriodicalIF":3.3,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12677941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145700997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a post-prescription audit and feedback antimicrobial stewardship intervention on inappropriate carbapenem prescribing: an interrupted time series analysis. 处方后审计和反馈抗菌药物管理干预对不适当的碳青霉烯处方的影响:中断时间序列分析。
IF 3.3 Q2 INFECTIOUS DISEASES Pub Date : 2025-12-03 eCollection Date: 2025-12-01 DOI: 10.1093/jacamr/dlaf236
Flavio Sangiorgi, Pierluigi Del Vecchio, Eugenia Magrini, Emanuele Rando, Beatrice Liguoro, Alessia Frater, Francesca Giovannenze, Massimo Fantoni, Carlo Torti, Rita Murri

Background: Antimicrobial stewardship programs (ASPs) are essential to improve antibiotic prescribing. This study evaluated the impact of a post-prescription audit and feedback intervention on carbapenem prescribing appropriateness in a large university hospital.

Methods: This retrospective observational study utilized interrupted time series (ITS) analysis, employing an Autoregressive Integrated Moving Average (ARIMA) model, to assess carbapenem prescribing across three consecutive phases: a 12-month pre-intervention, a 6-month intervention, and a 6-month post-intervention follow-up. Carbapenem prescribing appropriateness was retrospectively evaluated using an in-house developed algorithm, based on international and national guidelines and institutional protocols. The intervention involved bedside consultations by infectious diseases specialists employing a post-prescription audit with face-to-face feedback.

Results: We evaluated 1825 carbapenem therapies, primarily prescribed for suspected/confirmed bloodstream infections (46%, 843/1825). Among these, 458 (25%) were deemed inappropriate, mainly due to unnecessarily broad-spectrum use (72%, 331/458). The ITS-ARIMA model showed an immediate 11% reduction in the rate of inappropriate prescriptions during the first month of intervention phase (P = 0.001), followed by a non-significant downward trend during the remaining intervention period. However, an immediate 14.9% increase in inappropriate prescriptions was observed at the onset of the post-intervention phase (P = 0.001), indicating a rebound effect after the withdrawal of the active stewardship intervention.

Conclusions: Implementing a post-prescription audit and face-to-face feedback intervention was associated with a short-term improvement in carbapenem prescribing appropriateness. We observed a reduction in the trend of inappropriateness, although this change was not statistically significant. Future studies should investigate strategies for implementing sustainable ASPs optimizing human resources and time investment.

背景:抗菌药物管理计划(asp)对改善抗生素处方至关重要。本研究评估了一家大型大学医院处方后审计和反馈干预对碳青霉烯类药物处方适宜性的影响。方法:本回顾性观察性研究采用中断时间序列(ITS)分析,采用自回归综合移动平均(ARIMA)模型,评估碳青霉烯在三个连续阶段的处方:12个月的干预前、6个月的干预和6个月的干预后随访。根据国际和国家指南和机构协议,使用内部开发的算法回顾性评估碳青霉烯类药物处方的适宜性。干预措施包括由传染病专家进行床边会诊,采用处方后审计和面对面反馈。结果:我们评估了1825种碳青霉烯类药物,主要用于疑似/确诊的血流感染(46%,843/1825)。其中,458例(25%)被认为不适当,主要是由于不必要的广谱使用(72%,331/458)。ITS-ARIMA模型显示,在干预阶段的第一个月,不当处方率立即降低了11% (P = 0.001),随后在其余干预期间出现了不显著的下降趋势。然而,在干预后阶段开始时,观察到不当处方立即增加了14.9% (P = 0.001),这表明在主动管理干预退出后出现反弹效应。结论:实施处方后审计和面对面反馈干预与碳青霉烯类药物处方适当性的短期改善有关。我们观察到不恰当的趋势有所减少,尽管这种变化在统计上并不显著。未来的研究应探讨实施可持续asp的策略,优化人力资源和时间投资。
{"title":"Impact of a post-prescription audit and feedback antimicrobial stewardship intervention on inappropriate carbapenem prescribing: an interrupted time series analysis.","authors":"Flavio Sangiorgi, Pierluigi Del Vecchio, Eugenia Magrini, Emanuele Rando, Beatrice Liguoro, Alessia Frater, Francesca Giovannenze, Massimo Fantoni, Carlo Torti, Rita Murri","doi":"10.1093/jacamr/dlaf236","DOIUrl":"10.1093/jacamr/dlaf236","url":null,"abstract":"<p><strong>Background: </strong>Antimicrobial stewardship programs (ASPs) are essential to improve antibiotic prescribing. This study evaluated the impact of a post-prescription audit and feedback intervention on carbapenem prescribing appropriateness in a large university hospital.</p><p><strong>Methods: </strong>This retrospective observational study utilized interrupted time series (ITS) analysis, employing an Autoregressive Integrated Moving Average (ARIMA) model, to assess carbapenem prescribing across three consecutive phases: a 12-month pre-intervention, a 6-month intervention, and a 6-month post-intervention follow-up. Carbapenem prescribing appropriateness was retrospectively evaluated using an in-house developed algorithm, based on international and national guidelines and institutional protocols. The intervention involved bedside consultations by infectious diseases specialists employing a post-prescription audit with face-to-face feedback.</p><p><strong>Results: </strong>We evaluated 1825 carbapenem therapies, primarily prescribed for suspected/confirmed bloodstream infections (46%, 843/1825). Among these, 458 (25%) were deemed inappropriate, mainly due to unnecessarily broad-spectrum use (72%, 331/458). The ITS-ARIMA model showed an immediate 11% reduction in the rate of inappropriate prescriptions during the first month of intervention phase (<i>P</i> = 0.001), followed by a non-significant downward trend during the remaining intervention period. However, an immediate 14.9% increase in inappropriate prescriptions was observed at the onset of the post-intervention phase (<i>P</i> = 0.001), indicating a rebound effect after the withdrawal of the active stewardship intervention.</p><p><strong>Conclusions: </strong>Implementing a post-prescription audit and face-to-face feedback intervention was associated with a short-term improvement in carbapenem prescribing appropriateness. We observed a reduction in the trend of inappropriateness, although this change was not statistically significant. Future studies should investigate strategies for implementing sustainable ASPs optimizing human resources and time investment.</p>","PeriodicalId":14594,"journal":{"name":"JAC-Antimicrobial Resistance","volume":"7 6","pages":"dlaf236"},"PeriodicalIF":3.3,"publicationDate":"2025-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JAC-Antimicrobial Resistance
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1